#SFHS2604416AOrder of April 8, 2026 Amending the List of Pharmaceutical Specialties Covered in Addition to Hospitalization Benefits
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates the list of pharmaceutical drugs that the French healthcare system covers for specific hospital treatments. It includes drugs for treating certain fungal infections and visceral leishmaniasis when other treatments aren't effective or tolerated. Hospitals and pharmaceutical companies need to adjust to these changes.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Addition of specific drugs for certain fungal infections to the covered list
- Inclusion of treatments for visceral leishmaniasis resistant to other drugs
- Changes require adjustments from hospitals and pharmaceutical companies
Obligations
What this law requires
Hospitals must update billing systems to include Liposomal Amphotericin B (AMPHOTERICINE B LIPOSOMAL MEDIPHA 50 mg) as a billable pharmaceutical specialty in addition to hospitalization benefits under article L. 162-23-6 of the social security code
Healthcare providers must restrict coverage of Liposomal Amphotericin B for invasive Aspergillus infections solely to cases of voriconazole treatment failure or intolerance
Healthcare providers must restrict coverage of Liposomal Amphotericin B for Candida infections to patients with documented renal impairment (creatinine >220 micromol/L or creatinine clearance <25 mL/min) or pre-existing persistent renal dysfunction meeting these thresholds
Healthcare providers must restrict coverage of Liposomal Amphotericin B for neuro-meningeal cryptococcosis to HIV-infected patients only
Healthcare providers must restrict empirical treatment coverage of Liposomal Amphotericin B for presumed fungal infections to febrile neutropenic patients meeting criteria: allogeneic bone marrow transplant recipients or adults with neutropenia ≥7 days from antifungal introduction, and receiving concurrent nephrotoxic agents